Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10486172 | Value in Health | 2015 | 10 Pages |
Abstract
This study has shown overlap in the methods national/local REA bodies in Europe have chosen for a pazopanib REA for renal cell carcinoma, except for the use and methods of indirect comparisons. Although some additional comparators and outcomes differed between national/local REAs, they can be captured in a comprehensive joint REA.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Sarah MSc, Mohammed MSc, Michiel W. MD, PhD, Piet MD, MScBiostat, Bachir PhD, Angela MSc, MPH, Anthonius MD, PhD, Hubertus G. PharmD, PhD, Wim G. PhD,